Public-registry trials using MDR-101 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants | Medeor Therapeutics, Inc. | Kidney Transplant Rejection | PHASE3 | 19 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →